Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Deferred Revenue (2016 - 2025)

CytomX Therapeutics' Current Deferred Revenue history spans 12 years, with the latest figure at $28.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 69.7% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $28.5 million, down 69.7%, while the annual FY2025 figure was $28.5 million, 69.7% down from the prior year.
  • Current Deferred Revenue reached $28.5 million in Q4 2025 per CTMX's latest filing, up from $22.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $301.3 million in Q4 2022 to a low of $4.0 million in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $145.0 million, with a median of $145.0 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: plummeted 98.55% in 2023, then soared 4484.28% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $284.8 million in 2021, then rose by 5.82% to $301.3 million in 2022, then fell by 29.54% to $212.3 million in 2023, then tumbled by 55.7% to $94.1 million in 2024, then plummeted by 69.7% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Current Deferred Revenue are $28.5 million (Q4 2025), $22.4 million (Q3 2025), and $11.6 million (Q2 2025).